EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Systemic inflammation is associated with worse outcomes from SARS-CoV-2 infection but not neutralizing antibody

Christopher W Farnsworth iD, Brittany Roemmich, John Prostko, Gerard Davis, Gillian Murtagh, Laurel Jackson, Christopher Jacobson, Nicolette Jeanblanc, Timothy Griffiths, Edwin Frias, David J Daghfal

Microbiology Spectrum · 2025

DOI: 10.1128/spectrum.02459-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, 2025. Verfasst von Christopher W Farnsworth und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Immunology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA. Hauptthemen laut MEDLINE: COVID-19, Antibodies, Neutralizing, SARS-CoV-2, Inflammation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Abbott | Abbott Diagnostics (DIAGNOSTICS AT ABBOTT).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Systemic inflammation is associated with COVID-19 mortality rates, but the impact of inflammation on neutralizing antibodies to severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) and on outcomes is poorly understood. This study aimed to determine the association between neutralizing antibody responses, inflammation, and clinical outcomes in hospitalized patients with COVID-19. Two hundred and eight patients presenting to the ED with symptomatic SARS-CoV-2 were included. Neutralization was assessed using the architect angiotensin-converting enzyme-2 (ACE2) binding inhibition assay, and inflammation was assessed using C reactive protein (CRP) and interleukin 6 (IL-6). Medical records were examined for 30-day mortality and 10-day intubation. Correlation between biomarkers was assessed and Kaplan–Meier curves and Cox proportional hazards models were constructed for outcomes. Thirty-seven (18%) patients died and 59 (28%) required intubation. There was a correlation between IL-6 and CRP ( r = 0.34) but not ACE-2 ( r < 0.06). Patients that died had higher CRP (14 mg/dl, 8–21) than those that survived (5 mg/dl, 2–11) and IL-6 (died = 344 pg/ml, 138–870 vs. survived = 65 pg/ml, 28–140). ACE-2 inhibition trended higher in those who survived (18%, 0%–65%) than those who died (3%, 0%−48%). Patients with elevated IL-6, elevated CRP, or low ACE2 inhibition had higher mortality. Only IL-6 (hazard ratio: 1.28, 95% CI 1.08–1.52) and age (1.04, 1.01–1.08) were associated with mortality in multivariate models. Elevated IL-6 was associated with 30-day mortality from SARS-CoV-2 infection. Lower ACE-2 inhibition was not independently associated with mortality or correlated with inflammatory markers, implying the importance of other aspects of the immune response for reducing SARS-CoV-2 mortality risk. IMPORTANCE While systemic inflammation associated with worse outcomes from SARS-CoV-2 infection, it is not associated with neutralizing antibody concentrations, implying the importance of other aspects of the immune response for reducing SARS-CoV-2 mortality risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Antibodies, NeutralizingSARS-CoV-2InflammationAntibodies, ViralHumansMaleFemaleMiddle AgedAgedInterleukin-6C-Reactive ProteinAngiotensin-Converting Enzyme 2Aged, 80 and overBiomarkersAdult

Stichwörter der Autor:innen

SARS-CoV-2adaptive immunityinflammationneutralizing antibodies

Substanzen

Antibodies, NeutralizingInterleukin-6C-Reactive ProteinAntibodies, ViralAngiotensin-Converting Enzyme 2BiomarkersACE2 protein, humanIL6 protein, human

Autor:innen und Institutionen

  • Department of Pathology and Immunology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.
  • Abbott Diagnostics, Abbott Park, Illinois, USA.

ORCID-Profile: Christopher W Farnsworth

Förderung

  • Abbott | Abbott Diagnostics (DIAGNOSTICS AT ABBOTT)

Zitieren

APA

Farnsworth, C. W., Roemmich, B., Prostko, J., Davis, G., Murtagh, G., Jackson, L., Jacobson, C., Jeanblanc, N., Griffiths, T., Frias, E., & Daghfal, D. J. (2025). Systemic inflammation is associated with worse outcomes from SARS-CoV-2 infection but not neutralizing antibody. Microbiology Spectrum. https://doi.org/10.1128/spectrum.02459-24

Vancouver

Farnsworth CW, Roemmich B, Prostko J, Davis G, Murtagh G, Jackson L, et al. Systemic inflammation is associated with worse outcomes from SARS-CoV-2 infection but not neutralizing antibody. Microbiology Spectrum. 2025. doi:10.1128/spectrum.02459-24

BibTeX
@article{Farnsworth2025,
  author = {Farnsworth, Christopher W and Roemmich, Brittany and Prostko, John and Davis, Gerard and Murtagh, Gillian and Jackson, Laurel and Jacobson, Christopher and Jeanblanc, Nicolette and Griffiths, Timothy and Frias, Edwin and Daghfal, David J},
  title = {Systemic inflammation is associated with worse outcomes from SARS-CoV-2 infection but not neutralizing antibody},
  journal = {Microbiology Spectrum},
  year = {2025},
  doi = {10.1128/spectrum.02459-24}
}
Kostenlos starten →